Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors
- First Online:
- 7 Downloads
Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 9.Efstathiou JA, Bae K, Shipley WU, et al.: Cardiovascular mortality and duration of androgen deprivation therapy for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008 (in press).Google Scholar
- 16.Berruti A, Dogliotti L, Terrone C, et al.: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361–2367; discussion 2367.PubMedCrossRefGoogle Scholar
- 20.Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 (in press).Google Scholar
- 21.Smith MR, Lee H, McGovern FJ, et al.: Metabolic changes during gonadotropin releasing hormone (GnRH) agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008 (in press).Google Scholar
- 34.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.Google Scholar
- 44.Smith M, Malkowicz SB, Chu F, et al.: Toremifene improves lipid profiles in men receiving androgen deprivation therapy for prostate cancer-interim analysis of a multicenter phase III study. J Clin Oncol 2008 (in press).Google Scholar